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New methodologies to synthesize septa noses and extended ring systems are f 
i described using different divergent routes. Septanoses are the ring extended analogs of 
1 pyranose sugars. They are rare in nature presumably because of ring strain. Septanose j 
1 
! 
,j 
sugars have many high energy conformations. Out of 28, only four conformations are 
I low energy conformations. A major part of our research focuses on the synthesis of a 
stable septanose ring. Our inspiration for this project arose as we know that some 
1 septanose derivatives, such as those that bind concanavalin A, are glycosidase 
I inhibitors, and have been used to define new types of protein-carbohydrate interactions. 
I 
! 
 More conformations can allow more ways for the sugar to bind. 

I 
 The syntheses described are all accomplished by: ring opening of the hexose 

! sugars, stereoselective introduction of a carbon atom to the open chain; and 
I recyclization of the homologated structure to the septanose sugar. The starting material 
I 
! for these sequences is 2,3,4,6-tetra-O-benzyl-D-glucopyranose. In one scheme, the I 
I 
cyclic sugar was subjected to homologation of a carbon by a Wittig reaction, followed by 
oxidation of the resulting secondary alcohol then hydroboration/oxidation of the newly 
introduced alkene. Similarly, epoxidation of a sugar aldehyde was followed by 
concurrent intramolecular ring opening of the epoxide in basic conditions, to yield a I, 
}, xu 
septanose. Likewise, in a third route we first reduced the starting sugar with NaBH4 to 
give the acyclic diol. Both alcohol groups of the diol were converted into dicarbonyl 
groups and the dicarbonyl intermediate was then treated with thiourea to yield an 
extended ring compound having Nand S atoms in the ring system. 
I 

I 

I 
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Chapter 1 
An Introduction to Carbohydrates 
1. 1. Introduction 
Carbohydrates are the main source of energy in almost all organisms. 1 They are 
the most abundant of the four major classes of biomolecules on the earth. We cannot 
underestimate their roles in living organisms such as in energy transport and as being 
structural components of plants and arthropods. They are intermediates in the 
biosynthesis of fats and proteins.2 A carbohydrate is the term derived from the French 
word "hydrate de carbone" meaning hydrates of carbon. They also are called 
saccharides, derived from the Greek term "sakcharon" meaning sugar.3 Carbohydrates 
are naturally occurring molecules which are made up of carbon, hydrogen and oxygen. 
That is why they are called hydrates of carbon with the general formula Cn(H20)n. 
Chemically, carbohydrates can be defined as simple organic compounds that are 
polyhydroxylated aldehydes or ketones. They must have at least three hydroxyl groups 
attached to the carbon backbone. We will discuss the structure and classification of the 
carbohydrates in detail in section 1.3 of this chapter. 
When we talk about carbohydrate chemistry, it is against etiquette not to mention 
glucose, the most common and popular member of this class. Glucose plays an II important role in biological processes.4 Glucose is used as source for storage of energy
I 
\ such as in form of glycogen in animals alld starch in plants. It plays a key role in the 
I 
I 
J 
I 
I 
l 
existence and in the evolution of the life on the earth as they are directly linked between 
the energy of the sun and the chemical energy. For instance, glucose is produced 
during the process of photosynthesis. Photosynthesis is the process in which light 
energy from the sun is converted into chemical energy by combining carbon dioxide gas 
(C02) with water (H20) to form carbohydrates (C6H120 6) and molecular oxygen (02) as 
shown in Scheme 1.1. 
hv ( light energy from the sun) 
... 

photosynthesis 
Scheme 1.1 
Glucose is the body's primary source of energy. Our body catabolizes one 
glucose molecule into two equivalents of pyruvate by the process called glycolysis 
(Figure 1.1). Glycolysis is a series of ten enzyme-catalyzed reactions which involves ten 
intermediate compounds. 5 The intermediates provide entry points to glycolysis. For 
example, monosaccharides like fructose, glucose, and galactose can be converted to 
one of these intermediates. 
1 

i 
I 

2 
Figure 1.1. Glycolysis process. 
Image reproduced from: http://commons.wikimedia.org/wiki/File:Glycolysis.jpg 
Although, carbohydrates are considered as the sweetest molecules on the earth, 
they have a sour side too; which is their complexity. This complexity is due to the 
structure and chemistry of these molecules based on numerous hydroxyl groups. 
Specifically, hydroxyl groups are challenging for the organic synthetic chemists to work 
with due to issues related to solubility and chemical reactivity. As these hydroxyl groups 
are polar in nature, it is very hard to dissolve these molecules with organic solvents.6 
The necessity of protecting groups to protect these hydroxyl groups then arises for 
chemo- and stereoselective reactions. The most common protecting groups are acetyl 
or benzoyl esters and silyl or benzyl ethers7 which opens the doors for diverse reaction 
conditions for synthesizing new target compounds. 
i! 
! ) 
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1.2. Historical perspective of carbohydrates 
I 

Since ancient times, carbohydrates like cellulose, starch, and sucrose have been 
1 very well-known as they had great cultural influences by providing the societies clothing, 
I 
i 
I 
food, and shelter. For example, in 4000, B.C., the outer bark of the plant Cyperus 
Papyrus was used to make papyrus,S a material used for writing purposes. Starch was 
1 used by early humans as a part of their diet in vegetables and grains as well as to 
stiffen their clothes. 
In 975 C.E. an Arabian pharmacologist described the treatment of starch with 
saliva to produce a poultice for the treatment of wounds.9 He named that poultice as 
"artificial honey". Another ancient source for carbohydrates was sugar cane out of which 
sucrose was extracted. In 1792 a carbohydrate was found in honey which was not 
sucrose. Then in 1802, the same carbohydrate was found in grapes. Later, in 1811, it 
was discovered that acid hydrolysis of starch produced a carbohydrate which was same 
as the sugar found in grapes (and honey). Also, in 1820 research showed that urine of 
diabetics contains the same sugar. 10 
Finally, in 1838 this sugar was named as glucose. A well-known German 
Chemist August Kekule later changed the name to dextrose. In 1881! another sugar 
was isolated from honey initially named Levulose. But later in1890, the German 
Chemist Emil Fisher (Kekule's former student) renamed it fructose and changed the 
name of dextrose to glucose again. 11 
I 

1 
I, 
I, 
1 
i 
i ~ 
4 
1 

I 

I 1.3. Classification 
I 
I 
1 Carbohydrates are generally classified on the basis of their carbohydrate unit as 
either simple or complex. Simple carbohydrates, in their monomer form, are called i 
i monosaccharides (e.g. glucose and fructose that cannot be converted into smaller I sugars by hydrolysis). Complex carbohydrates are made of two or more simple sugars I 
linked together. Sucrose is a disaccharide made up of one glucose linked to a fructose 
molecule. Similarly, cellulose is a polysaccharide made up of several thousand 
glucose units linked together by a glycosidic bond. These polysaccharides are broken 
down into their monosaccharides units by enzyme-catalyzed hydrolysis.12 Some 
examples of mono-, di-, and polysaccharides are shown in Figure 1.2. 
I 
! 
I 5 
I 
f j 
Figure 1,2. Examples of mono, di and polysaccharides. 
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Monosaccharides are further subdivided as either aldoses or ketoses. The suffix 
-ose indicates a carbohydrate while prefixes a/do- and keto- stands for the kind of 
carbonyl group present, whether aldehyde or ketone. 
All ketoses and aldoses are further subdivided on the basis of number of carbon 
atoms in the chain by putting a numerical term tri-, tetra-, penta-, hexa-, and so on, 
between aldo- and -ose in the name as shown in Figure 1.3 and 1.4. 
\ 
1 
I 6 
Figure 1.3. Classification of aldoses. 13 
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Image reproduced from: http://www.science.fau.edu/chemistry/marilbiochemlabimanual.htmI 
7 
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Figure 1.4. Classification of ketoses. 13 
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Image reproduced from: http://www.scienceJau.edu/chemistry/mari/biochemlab/manual.html 
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1.5. Furanose and pyranose forms 
In solution, the open-chain form of glucose exists in equilibrium with different 
cyclic isomers.14 The cyclic forms occur because of a nucleophilic addition reaction 
between the hydroxyl group of C-4 or C-5 and the carbonyl functionality at C-1. Either 
hemi-acetals or hemi-ketals form depending on the type of sugar (i.e. aldose or ketose). 
If the C-4 hydroxy closes the ring then the cyclic form of the glucose is known as the 
furanose form, after the 5-membered ring cyclic ether furan while if C-5 hydroxy 
cyclizes, then the ring formed is called pyranose form, after the six-membered ring 
cyclic ether pyran, as shown in the Figure 1.5. 
Figure 1.5. Pyranose and furanose forms of glucose. 
6 
5 
6 
HOH2C Pyranose Form\ 
5 CH-~
'\ H 
OH I 
OH c~ 
410 
0- Glucose Furanose Form 
9 
In aqueous solution, more than 99% of glucose molecules exist in the pyranose 
form while the open chain form of glucose is limited to about 0.25%.15 The furanose 
form also exists in almost negligible quantity. When we refer to term glucose, this 
usually refers to the cyclic forms. 
Out of the two, the pyranose form is more stable than the furanose form because 
of attaining six membered ring structure. 16 The pyranose and furanose forms are further 
subdivided on the basis of how they cyclize. During the cyclization, the anomeric carbon 
(the hemiacetal carbon atom originating from the carbonyl oxygen) becomes a 
sterogenic center with 2 possible configurations (a: or P) depending on the way they 
cyclize. The resulting isomers are called anomers and tbis property is called 
mutarotation. Mutarotation is the change in optical rotation that occurs by epimerization 
at the anomeric center. That means, it is the change in the equilibrium between two 
epimers, when the corresponding stereocenters interconvert. Cyclic sugars show 
mutarotation as a: and panomeric forms interconvert in the solution. In aqueous 
solution, D-glucose exists as a mixture of 36% a: form and 64% p form (>99% of cyclic 
form exists as a pyranose). The Pform is favored because all of the hydroxyl groups are 
in equatorial position, while in minor a: anomer, one hydroxyl group is forced into the 
axial position which causes high energy in the molecule and makes it less stable. The 
equilibrium occurs via the ring opening of the cyclic sugar at the anomeric center with 
the acyclic form as the intermediate. The a: and Panomers form because of the C 1-C2 
bond rotation of the acyclic sugar and the subsequent ring closure to the pyranose form 
(Figure 1.6). 
, 
I \0 
j 
i 
I 
I 
I 
Figure 1.6. Anomers of D-glucose. 
H 
.. 
n-D-Glucopyranose
Bond rotation (C1-C2) 11 
H H 
• 
H H 
p-D-Glucopyranose 
The most stable conformations of the six-membered ring form of glucose are the 
(i) chair conformations and the (ii) boat conformations. In these conformations, the ring 
is bent so that the bond lengths and angles are close to those ideal values (109.50 for 
Sp3 carbon) which have less strain energy than a flat ring with 1200 angles. Out of the 
two, the chair conformation is more stable than the boat conformation. The boat 
conformation has the steric as well as torsional strain 17 and is approximately 17 kJ/mol 
(4 kcal/mol) less stable than the chair conformation. 
j 
1 
I 
11 
Figure 1.7. Examples of chair and boat conformations of glucose. 
HO 
OH 
HO 
Chair Boat 
The structures of monosaccharides are usually represented in three forms 
(Figure 1.8): 
1) Fisher projection: straight chain representation, 
2) Haworth projection: simple ring in perspective, and 
3) Conformational representation: chair and boat configurations. 
Figure 1.8. Structural representations of D-glucose. 
HC90 HO HO 
H OH 
HO H 
H OH 
H OH 
OH OH H OH H H CH20H 
p-forma.-forma.-form p-form 
Fisher projection Haworth projection Conformational representation 
12 
1.5. Septanose form 
As discussed in section 1.4, aqueous solutions of aldoses contain complex 
mixtures. Detailed studies show that the equilibrium mixture of hexose sugars consists 
at least six forms: two pyranoses, two furanoses, an aldehyde isomer, and a hydrate of 
the aldehyde form.18 In addition to these, two other cyclic isomers can exist that are 
named as septanoses, based on a 7 -membered ring carbohydrate. 19 Like pyranoses 
and furanoses, septa noses differ by the configuration at the anomeric center as shown 
in Figure 1.9. 
Figure-1.9. Structure of glucoseptanose. 
OH H OH H 
a-D-Glucoseptanose p-D-Glucoseptanose 
Studies on septa noses are limited as they are very unstable. 19 Such structures 
were isolated only for D-idose. According to the 13C NMR data a solution of D-idose at 
370 C contains 1.6% of a mixture of septanose anomers.20 
I 
I 
1 
I 
1 13 
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I 1.6. Biological activity of carbohydrates 
I 

I Carbohydrate derivatives can be potent therapeutic agents.21 For a long time, the biological importance of carbohydrates was underestimated by the pharmaceutical and j 
academic societies. They used to be thought of as dull molecules whose only functions 
were providing energy and in cell wall construction.22 Recent studies validate their 
significance in medicinal chemistry programs, such that biochemists are presently 
exploring the role of carbohydrates in proteins binding and activity in a hot area of 
research coined glycobiology.23 
In the early ages, people found the cures for their illnesses by chewing the 
herbs, roots, barks etc. of plants. Some of these remedies were successful but the real 
j 
knowledge of the actual constituents of those herbs was unknown.24 With advances in I 
research capabilities, scientists became able to identify the constituent compounds 1 
i found in the plants. For example, by the middle of the sixteenth century, people used 
the extract of cinchona bark for chills and fevers. Later in 1820, the active constituent of 
I the cinchona bark was isolated and was found to be quinine, an antimalarial drug.25 
Another remedy was an extract of fox glove plant was used for the treatment of 
congestive heart failure (dropsy) in 1785. The active constituents of this plant were 
found to be secondary glycosides digitoxin (Figure 1.10) and digoxin (Figure 1.11) from 
1 
I 
1 Digitalis purpurea and Digitalis lanata (fox glove plants).26 The latter are in clinical use 
for congestive heart failure and are manufactured by the extract of fox glove plants25. 
I 
\
•l 14 
1 
Figure 1.10. Structure of Digitoxin. 
Digitoxin 
Figure 1.11. Structure of Digoxin. 
Digoxin 
Today, many carbohydrate derivatives playa significant role in drug design and 
development 25. For example, monosaccharides such as ascorbic acid own a broad 
spectrum of bio-activity and applications in medicine.27 Another name for this molecule 
i 
I, 
I is vitamin C which is present in citrus fruits. But a deficiency of vitamin C causes the 
,j disease scurvy which can be treated by ascorbic acid. Among monosaccharides, two 
1 15 
amino sugars are antibiotics that are well-known. Streptozotocin28 and Prumycin,29 they 
both have anti-tumor activity. Streptozotocin is a naturally occurring compound which is 
toxic to the insulin- producing beta cell of the pancreas in mammals and potentially 
implicated in diabetes. This drug is potent to treat cancers of the Langerhans. 21Another 
simple sugar with antiepileptic activity is known as Topiramate. 3o The anticonvulsant 
properties of Topiramate were discovered through biological screening. Structures of 
these drugs are shown in Figure 1.12. 
Figure 1.12. Monosaccharides as therapeutics. 
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Among disaccharides the very well-known and the first therapeutic which is still in 
clinical use is Lactulose. 31 Lactulose is used for the treatment of hepatic coma. It is also 
used to treat constipation and for regulating ammonia concentrations in the blood. It is 
16 
synthesized commercially by the isomerization of lactose.32 It consists of two 
monosaccharide units, fructose and galactose. Another classical example of this class 
of sugars is Sucralfate - an aluminum hydroxide complex of sucrose sulfate. 21This drug 
is currently being used in the therapy of duodenal ulcers (Figure 1.13). 
Figure 1.13. Disaccharides as therapeutics. 
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1.7. Summary 
Carbohydrates are the most abundant and common biomolecules in nature. 
They are the major source of energy in living organisms. Carbohydrate derivatives are 
actively involved in fertilization, immune system development and in the treatment of 
diseases. Glucose is a biologically- significant monosaccharide involved in metabolic 
and energetic pathways. Glycoconjugates, in which the carbohydrate moiety is 
covalently linked with other chemical species, also have very important roles in biology 
17 
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(e.g. glycoproteins, glycopeptides, peptidoglycans, and glycolipids). All organisms 
depend on carbohydrates and glycoconjugates to maintain their life. 
In short, carbohydrates play vast and diverse roles in biological systems. 
Because this was not previously recognized, medicinal and pharmaceutical applications 
have not been fully pursued. Now, synthetic medicinal chemists have made major 
contributions towards novel target compounds as a variety of carbohydrate derivatives 
are serving as potent therapeutics. Both simple and complex carbohydrates are playing 
roles in treating human diseases like diabetes, cancer and infections. 
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Chapter 2 
Septanoses 
2. 1. Introduction 
Seven-membered ring sugars (septa noses) are uncommon in nature as the 
thermodynamic preference is for five- and six-membered furanose and pyranose 
rings. 16 Since general methods of carbohydrate synthesis favor furanose and pyranose 
isomers over their seven-membered ring structures, this area of research has remained 
largely unexplored. 
Our inspiration for the synthesis of septanose carbohydrates is based on the 
development of glycosidase inhibitors. Septa noses may represent good candidates for 
glycosidase inhibition because of its many conformations.33 In the key biological 
process where a carbohydrate moiety binds a lectin (a carbohydrate-binding protein)34, 
the conformational preferences of septanose carbohydrate may enhance the protein-
carbohydrate interaction. 
I 
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 2.2. Conformations 
I 

I Because of ring strain, septa nose sugars do not exist in great abundance 
i naturally. There are 28 conformations available to the septanose.35 In general; seven 
I 
I 
membered ring systems show four low energy conformations. These are: (i) twist-chair 
(TC), (ii) chair (C), (iii) twist-boat (TB), and (iv) boat (B). Among the four, the twist chair 
t 
is the most stable by 4kcal/mol. 35 
I 
I 
Figure 2.1. Conformations of glucoseptanose.. 
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It is known that none of the unprotected aldo-hexoses exist as septanoses in 
aqueous solution to any great extent.36 However, if the hydroxyl groups at positions C4 
20 
and C5 are substituted to prevent the formation of pyranoses and furanoses, like in 
2,3,4,5-tetra-O-methyl-D-glucose, then septanose sugars may be formed as shown in 
Figure 2.2. 
Figure 2.2. Structure of septanose. 
(ii) 2,3,4,5-tetra-O-methyl-a-D­(i) 2,3,4,5-tetra-O-methyl-I3-D­
glucoseptanoseglucoseptanose 
Septa noses exhibit 14 unique low energy TC conformations. The most stable 
conformers are shown in Figure 2.3.37 For these conformers three atoms define a 
molecular plane and the remaining atoms lie above or be/ow the plane. In the case of 
3.4TC5,6. for example, molecular oxygen, C1 and C2 are coplanar with each other while 
C3 and C4 are above the plane and C5 and C6 are below the plane. An axis of 
pseudosymmetry is centered on C1 of the 3.4TC5,6 conformation. The same applies for 
6,oTC4•5 conformer. The atoms or substituents at this position are called isoclinal 
because they have the same steric environment on the top of the ring as well as the 
bottom of the ring37 as shown in Figure 2.3. 
Figure 2.3. Twist chair conformation of glucoseptanose. 
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2.3. Septanoses as Glycosidase inhibitors 
Complex carbohydrates are formed by the linkage of monosaccharides. Two 
residues of monosaccharides join together by a glycosidic bond. A glycosidic bond is 
defined as a bond between anomeric hydroxyl group of the sugar residue and a 
hydroxyl of another sugar or some other compound, with a removal of a water molecule. 
A glycosidic bond is therefore a bond formed by the condensation of two 
monosaccharides and removal of one water molecule. The enzymes required to break 
glycosidic bonds are called hydrolases (glycosidase) i.e. enzymes requiring water and 
catalyze glycosidic bond hydrolysis (Figure 2.4.). 
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Figure 2.4. Hydrolysis of a glycosidic bond. 
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Glycosidases are involved in a broad range of biological and pathological 
processes. They have a variety of uses, for example, in the degradation of plant 
material like cellulose to the monosaccharide glucose. In the food industry, there is a 
glycosidase called invertase which is used to manufacture invert sugar and amylase 
and to break down starch into table sugar. 38 In the paper and pulp industry, xylanases 
are used for removing hemicellulose from paper pulp.39 Glycosidases are also actively 
involved in the process of digestion, in the biosynthesis of oligosaccharides, and in 
quality control processes of the endoplasmic reticulum (ER), such as ER- associated 
degradation of glycoproteins and catabolism of glycoconjugates.4o 
Although the role of these enzymes is very important for maintaining life but 
there are some disorders in which enzyme inhibition is desired for therapeutic 
applications. Glycosidase inhibitors are currently of great interest as potential 
therapeutic agents for anti-viral,41 anti-proliferative42 or anti-diabetic treatments. 43 
Almost 40 years ago, the classic glycosidase inhibitor nojirimycin was discovered from 
the culture broth of Streptomyces species.44 After that hundreds of glycosidase 
\ 
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inhibitors were isolated from different plants and many were synthesized on the same 
template. Glycosidase inhibitors are a widespread class of molecules that are used as 
agrochemicals as well as potent therapeutics.45 
Agrochemicals refer to a broad range of pesticides including insecticides, 
herbicides and fungicides.45 One of the very well-known classes of these enzymes 
which serves as glycosidase inhibitors are the Trehalase inhibitors.46 They inhibit the 
enzyme Trehalase which hydrolyses a sugar known as trehalose. Trehalose is a blood 
sugar in insects and a major storage sugar in fungi and yeast. Therefore these inhibitors 
serve as potent insecticides or fungicides. One of the very common trehalase inhibitors 
is known as Trehazolin47 as shown in Figure 2.5. 
Figure 2.5 Structure of Trehazolin. 
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I Other inhibitors are chitinase inhibitors48 with strong inhibitory activity towards 
chitinases which is the key enzyme for the ecdysis for the insects. Studies show that 
I 
I 
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these inhibitors have disruptive effects on biosynthesis of chitin. Allosamidin49 is a 
classic example of this type of inhibitor (Figure 2.6). 
Figure 2.6. Structure of Allosamidin. 
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As mentioned earlier, nojirimycin is a potent glycosidase inhibitor 44. It was 
discovered as the first glucose analog with the oxygen ring atom replaced with a 
nitrogen atom. This feature classifies this kind of therapeutics as aza-sugars. Aza­
sugars have a broad spectrum of activity, including potent glycosidase inhibition.5o This 
class of compounds contains poly-(hydroxypiperdines) and poly-(hydroxypyrrolidines) in 
their structures. This class of analogues serves as specific glycosidase inhibitors, as 
potential antidiabetic51 and anti-tumor agents.52 Figure 2.7 shows a few actively potent 
aza-sugars. Swainsosine and Castanospermine belong to the class of indolizidine 
alkaloids and are used in chemotherapy 21. 1-Deoxynojirimycin and 1­
Deoxymannojirmycin are derivatives of Nojirimycin. 
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I Figure 2.7. Structures of Aza-sugar glycosidase inhibitors. 
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Previously, it was mentioned that the lectin (a carbohydrate binding protein) of 
jack bean known as concanavalin A binds septa nose carbohydrates. The 
monosaccharide ligands that binds to concanavalin A are p-septanosides that also act 
as a glycosidase inhibitors.53 They act as substrates for Agrobacterium sp. p­
glucosidase.54 The ability of concanavalin A to bind a seven membered ring 
monosaccharide has been investigated by isothermal titration and saturation transfer 
difference NMR spectroscopy. 54 
I 
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2.4. Synthetic approaches to septanoses in the literature 
In the literature, much work has been done to synthesize five or six membered 
heterocycles. Only within the past ten years have scientists begun working on the 
synthesis of septanoses. They have been prepared from reducing sugars by the 
Baeyer-Villiger oxidation of inositols, by condensation of dialdehydes with active 
methylene compounds, by pyridinium chloride mediated ring opening of a protected 
gluco pyranosides and by the Bayer-Fischer reaction of sugar dialdehydes.55 In 
addition, Hoberg also has mentioned variety of methods to synthesize seven-membered 
oxacycles in his review article. 56 
More recently, Peczuh and his research group began synthesizing septanose 
derivatives. They reported the synthesis of oxepines using a ring-closing metathesis 
(RCM) approach starting from tetra-O-benzyl-D-glucose.57 
2.4.1. ReM approach starting from tetra-O-benzyl-D-glucose: 
RCM (ring closing metathesis) is a method for the cyclization of dienes using 
organometallic catalysts like the Shrock 5 or Grubbs 6 reagents (Figure 2.8). In this 
three-step methodology, Peczuh and his group reported the synthesis of tetra-O-benzyl 
oxepine 4 in 92% yield. The sequence of reactions started with commercially-available 
2,3,4,6-tetra-O-benzyl-D-glucopyranose 1 which was subjected to Wittig olefination to 
prepare 2. Compound 2 was converted to the vinyl ether 3, a precursor for RCM by 
27 
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1 treating with ethoxyethane, using Pd (II) in the presence of phenanthroline. Compound 
f 
3 was heated in toluene in the presence of the RCM catalyst (Shrock or Grubbs). They 
reported that no product formation was observed when using the Grubbs catalyst while 
the Shrock catalyst converted the diene 3 into tetra-O-benzyl oxepine 4. (Scheme 2.1) 
BnO OH ?" 
OBn 
Bno~BnOyOyOH (ii) BnO O?" (iii) 0 ~ 
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42 31 
Reagents and Conditions: (i) BuU, P(PhbCH3Br, THF, 74% (ii) Pd(OAch 
Phen.,Ethoxyethene, 80% (iii) Shrock(20 mol%), PhCH3 60 DC, 92% 
Scheme 2.1 
Figure 2.8. Structures of Shrock and Grubbs catalyst. 
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2.4.2. Cyclization-elimination route to septanose glycals: 
In 2004, Peczuh and his group also reported a five-step synthesis of oxepines 
from hept-1-enitols (Scheme 2.2) using an oxidation-reduction sequence.58 The known 
hept-1-enitol 7 was transformed into compound 8 in two steps by first protecting the 
hydroxyl group as its triethylsilyl ether and then by hydroboration-oxidation of the olefin. 
The resulting hydroxyl of 8, was subjected to Swern oxidation and submitted to 
acetalization conditions by using p-toluenesulfonic acid (p-TsOH) in methanol. They 
reported the deprotection of the silyl ether and cyclization/acetal formation to occur in 
one pot to form 9. Subsequently, elimination of methanol provided oxepine 10. 
H OH H H (i) (ii) 
.. Bno~R3(iii) (iv~BnO BnO~O~OCH3 
BnO ---... BnO ~ BnO~BnO (2 steps) BnO (2 steps) ~ BnOOH 
7 8 9 
H 
(v) Bno~O--'" ~ Bno~ 
BnO 
10 
Reagents and Conditions: (i) TESClffBSCI, Imidazole, OMF (ii) BH3.THF; H20 2, NaOH 
(iii) (COClh, OMSO, TEA (iv) p-TsOH, CH30H (v) TMSOTf, OIPEA, OCM. 
Scheme 2.2 
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2.4.3. Synthesis of septanosyl-1 ,2,3-triazoles: 
In 2007, Peczuh reported the synthesis of a septanose N-glycoside. In this 
synthesis, oxepine 11 was converted to septanosyl-1, 2,3 -triazoles 13 (Scheme-2.3).59 
Epoxidation of compound 11 using OMOO provided a 1 ,2-anhydroseptanose which was 
not isolated and was carried to the next step by treating with tetrabutylammonium azide 
in OeM to form 12. Finally, triazole 13 was made by Huisgen dipolar cycloaddition of 12 
with diethyl acetylene dicarboxylate in refluxing toluene (Scheme 2.3). The other 
derivatives of triazoles were also synthesized and each of the triazoles was evaluated 
for activity against glycosidases such as (1.- glucosidase, ~-glucosidase, (1.­
galactosidase, ~-galactosidase (1.-mannosidase, and ~-mannosidase. 
HO 
N R1 
Nil X B~ 'N R2B~ (i) (iii) 
BnO ---I.... 
.. BnO 
BnO~ BnO~ 
OH 
1311 12 
Reagents and Conditions: (i) DMDO, DCM, 0 DC (ii) NaN3. DMF/H20, RT 22% (iii) 
Diethyl Acetylene Dicarboxylate, Toluene, 110 DC, 70% or alkyne, Cu(OAc)z, 
Sodium Ascorbate, t-BuOH/H20, RT, 52-70%. 
Scheme 2.3 
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2.4.4. Cyclopropanation/ring expansion route to septanose carbohydrates: 
In 2007, another new route to synthesize septanoside derivatives from 
hydroxygalactal was reported by Jayaraman.6D In this synthesis, they started the 
sequence with the vinyl ether synthon 14 and the cyclopropanation of 14 with TEBAC in 
the presence of chloroform yielded cyclopropanated dichloro aduct 15. The ring was 
expanded by treating the cyclopropanated adduct with sodium methoxide and dioxane 
to generate oxepine 16. The Ru04-mediated oxidation was conducted to obtain a diketo 
derivative 17. The NaBH4 reduction to this diketo derivative led to the formation of a diol 
which was basically the septa nose 18 (Scheme 2.4). 
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----l~~ Bno_)--\o ---~. BnO "'IIOH 
BnO ° BnO OH 
17 18 
° 
Reagents and Conditions: (i) CHCI3, TEBAC, 40 DC, aq. NaOH (50%), 3 h, 85% (ii) 
NaOMe,1 A-dioxane, reflux, 2 days, 95% (iii) RuCI3, NaI04, H20, CH3CN, CCI4, 8 h, 0 
°c -RT, 75% (iv) NaBH4, MeOH, 0 DC - RT, 83%. 
Scheme 2.4 
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2.4.6. McDonald's endo-Selective Alkynol Cycloisomerization: 
In 2004, McDonald and his research group reported the three step synthesis of a 
septa nose 61 starting from known ribofuranose acetonide 19. An alkynyl alcohol 20 was 
formed by using a diazophosphonate reagent for homologation. The loss of a tert­
butyldiphenylsilyl group was reported. Tungsten-catalysed cycloisomerization of 20 
gave oxepine 21 in 68% yield (Scheme 2.5). They also reported the importance of 
isopropylidene protection, as this group tethers the terminal alkyne and diol functional 
groups in close proximity for the heterocyclization reaction. 
19 20 21 
Reagents and conditions: (i) K2C03, MeOH, MeC(O)C(N2)P(O)(OMeh, 65 DC, 50% 
(ii) 15 % W(CO)6, Et3N, THF, hv (350nm) ca.65 DC, 6 h. 
Scheme 2.5 
2.4.7. Steven's Septanose Synthesis: 
In this synthesis, Steven and his research group synthesized a septanose 
starting from D-glucose.62 Treatment of D-glucose with a mixture of hydrochloric acid in 
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acetone and methanol yielded D-glucoseptanoside 22 and 23 in 45% yield after eight 
days reaction. Compounds 22 and 23 were treated with milder acidic conditions which 
resulted in acetonide cleavage to yield unprotected alpha and beta methyl glycosides 24 
and 25 in 80% and 88% respectively (Scheme 2.6). 
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2.5. Summary 
Septanoses are seven membered ring sugars which because of their ring strain 
rarely occur in nature. Conformational studies are ongoing in order to attain greater 
knowledge concerning their stability. There is evidence in the literature for the 
recognition of a naturally occurring septa nose by concanavalin A. This evidence has led 
us to develop synthetic steps to prepare septanose derivatives. The newly prepared 
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septanoses are expected to be good ligands for glycosidases due to their enhanced 
conformational flexibility relative to 6-membered ring sugars. 
Several research groups have synthesized septanoses in different ways. 
Conformational studies on septa noses are limited but they show potential in assessing 
biological activities. There is much to explore for organic and bioorganic chemists 
regarding the nature of septanose-protein interactions and the developments of the 
analogues that can serve as tools for glycobiology. 
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Chapter 3 
Extended Ring Systems 
3. 1. Introduction 
The term "extended ring system" covers a broad range of compounds such as 
macrocyclic compounds (e.g. crown ethers, Figure 3.1) or compounds having macrolide 
rings (e.g. Erythromycin A, Figure 3.2) or Spinosad (Figure 3.3). Here, we have to 
narrow down the window for this term. To remain concise, in this chapter, we will 
discuss members of the classes of compounds that have seven- or eight-membered 
ring systems, specifically heterocycles. 
Figure 3.1 Common structures of crown ethers. 
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Figure 3.2. Structure of Erythromycin A. 
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Figure 3.3. Structure of Spinosad. 
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3.2. Heterocyclic compounds 
If we further narrow down the extended ring systems, we highlight seven or eight 
membered heterocycles. Heterocycles are the cyclic compounds in organic chemistry in 
which at least one carbon atom of the cycle is generally replaced by oxygen, nitrogen or 
sulfur. These heterocycles are classified on the basis of: 
1- The number of atoms in the ring 
2- Saturated or unsaturated ring 
3- Type of atom/atoms replaced by the carbon atom. 
For seven membered heterocycles, the suffixes -panes (for saturated) and-
pines (for unsaturated) are used. If one of the carbon atoms of the ring is replaced by an 
oxygen atom, then it will be an oxapane or oxapine depending on the degree of 
unsaturation. While, if a carbon atom is replaced by a nitrogen atom, it will be an 
azapane or azapine. Similarly, a prefix thia- will be used for a heterocycle in which a 
carbon is replaces by a sulfur atom. (e.g. thiapane or thiapene). 
Figure 3.4. Structures of seven membered heterocycles. 
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But not always is just one carbon atom of the cycle replaced with the other 
atoms. When two oxygen, nitrogen or sulfur atoms are present in the ring, the prefix 
dioxi-, diaze-, and dithia- will be used. Sometimes, carbon atoms of the cycle are 
replaced by two different types of atoms. For example, a seven membered heterocycle 
having sulfur and a nitrogen atom present in the cycle will be called 
thiazapane/thiazapine (suffix thia for sulfur and aza for nitrogen). 
Figure 3.5. Structure of thiazepanes. 
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Thiazapane 
Azepane, thiepane and thiazepane derivatives are gaining much attention in 
medicinal chemistry and pharmaceuticals because of their biological activities 
In 2004, new azepane derivatives were synthesized and found to serve as 
protein kinase B (PKB) inhibitors.53 These derivatives were also potent inhibitors of PKB 
in vitro and in various tumor cell lines. In this research paper they also mentioned that 
the derivatives possessed anti-cell proliferation properties and induced apoptosis. 
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Fjgure 3.6. New Azepane derivatives. 
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In 2008, substituted 2- oxo-azepane derivatives were found to be potent and 
orally active y- secretase inhibitors.64 y -secretase is a main proteolytic enzyme involved 
in Alzheimer's disease. The most well-known substrate of y- secretase is amyloid 
precursor protein. Alzheimer's disease is a disease caused when amyloid is deposited 
in the brain in extracellular plaques and intracellularly in neurofibriles. The amyloid 
plaques are composed of A~ peptides, whose production and deposition is the ultimate 
cause of Alzheimer's disease. 
Some thiepane derivatives were also synthesized and evaluated as glycosidase 
inhibitors in 2002.65 From the readily available thiepanes, enantiomerically pure 3,6­
diazido and 3,6-diamino-4,5- dihydroxythiepanes were synthesized and were found to 
be potent glycosidase inhibitors. 
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Figure 3.7. Structures of thiepane derivatives used as glycosidase inhibitors. 
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Besides azepanes, thiazepanes and diazepanes , there is another class of 
heterocycles worth mentioning known as the benzothiazepines. These molecules are 
discussed in detail in the next section. 
3.3. Benzothiazepines and their biological activity 
Benzothiazepines are compounds consisting of a thiazepene ring fused with a 
benzene ring structure. Benzothiazepines are considered as calcium channel blockers 
in medicinal chemistry.55 Their activity is an intermediate class between 
phenylalkylamines and dihydropyridines. Benzothiazepines have both cardiac 
depressant and vasodilator activities. 57 Therefore they are able to reduce arterial 
pressure without producing the same degree of cardiac stimulation caused by 
dihydropyridines. The main representative of this class is Deltiazem (Figure 3.8). 
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Figure 3.8. Structure of Diltiazem. 
Deltiazem 
Deltiazem is a drug which is used to treat high blood pressure, angina pectoris 
and some kinds of arrhythmia. The biological activity of benzothiazepines is not only 
limited to calcium channel blockers but also some analogues serve as potent 
tranquilizers,68 antidepressants,69 eNS stimulants,70 antihypertensives,71 and antiulcer72 
drugs. A graphical diagram summarizes these properties in Figure 3.9. 
Figure 3.9. Benzothiazepine as therapeutic agent. 
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Besides these, another potent action of this class was as antiarrhythmic drugs.73 
K201 (Figure 3.10) is a novel 1,4 benzothiazepine drug with cardioprotective and 
antiarrhythmic properties.74 This drug also possesses natriuretic, diuretic, and 
vasodialating properties which may support the role of this drug in the treatment of heart 
failure. 
Figure 3.10. Structure of K201 drug. 
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3.3. Synthetic approaches to Benzothiazepines in the literature 
In the literature there has been much work reported on the synthesis of 
benzothiazapine therapeutics. In 2009, the first 1,5 benzothiezapine derivatives were 
synthesized 72,75 in three steps by Knoevenagel condensation of aldehydes with 2,4­
ketoester 27 in anhydrous benzene in the presence of piperidine to yield compound 28. 
Then Michael addition of 28 with o-aminothiophenol in the presence of methanol gave 
ketoester derivative 29. Finally compound 29 was cyclized by dehydration in acetic 
acid/methanol to provide derivatives of compound 30 (Scheme 3.1). In this paper, 
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derivatives were synthesized with X as H or a CI group while R was varied as p-N02, 0­
N02 , p-CI, o-CI, P-CH3, p-OH, H, P-OCH3, p-F, and 2,4-dichloro groups. 
H2N 
R 0 U CHO H 
0 HS~ )-xH c)LO-C2Hs 0-H=\=OC2 • 
2 I~~ clrCH31# + (i) .. CH3 .. 0 #' (ii) 
28 02726 
(iii) s 
.. ~ X~N 
o H 
29 
Reagents and Conditions: (i) Piperidine, benzene, reflux 2 h. (ii) Methanol, RT, 1 h. (iii) 
Acetic acid, pH 3-4. 
Scheme 3.1 
A series of novel methylene-bis-benzofuranyl-[1 ,5]-benzothiazepines were 
synthesized in 2008 and found to be biologically active against Gram-positive and 
Gram-negative bacteria and fungi. 74 These derivatives were prepared by the reaction of 
salicylaldehyde 31 with trioxanein presence of a mixture of acetic acid and conc. sulfuric 
acid to generate 5-(3-formyl-4-hydroxybenzyl)-2-hydroxybenzaldehyde 32. The 
condensation of 32 with methyl ketones afforded methylene-bis-chalcones 33. The 
series of 33 was reacted with 2-aminothiophenol to get 34 in good yield which later 
were converted into bioactive 35 on condensation with alpha-bromoacetophenone, in 
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the presence of anhydrous K2CO~dry acetone and catalytic amount of KI, followed by 
cyclization in ethanolic KOH (Scheme 3.2). 
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d) 4-MeO-C6H4 
e) 4-02N-CsH4 
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Scheme 3.2 
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We were also inspired by a synthetic method found in literature for 1- and 5- Aryl­
2,4-benzothiazepines done in 1977.75 A series of benzothiazepines were synthesized in 
two steps starting from 2-hydroxymethylbenzhydrol 36. Compound 36 was brominated 
by treating with PBr3 to yield dibromo intermediate 37. The dibromo intermediate was 
then cyclized by treating with substituted thioureas to yield a benzothiazepine derivative 
38 (Scheme 3.3). Inspired by this methodology, our ultimate goal was to synthesize a 
seven or eight membered ring sugar by treating an acyclic dibromo derivative of our 
starting sugar with compounds like thiourea. 
(i) (ii) 
NR1CX;". C\=SI r• # Br • # NR2 
C6HS C6Hs 
36 37 38 
Reagents and Conditions: (i) PBr3, anhyd. CHCI3, RT, 4 days (ii) Substituted Thioureas, 
anhyd. Acetone, gentle reflux, 96 h, Na2C03. 
Scheme 3.3 
3.4. Summary 
Extended ring systems in organic chemistry are a wide range of compounds with 
medicinal and biological importance. Most of the compounds are naturally occurring. 
Many serve as therapeutic agents. In particular, extended ring systems having seven or 
eight membered rings such as: sesquiterpene lactones, cyclooctanoids, azepanes, 
thiazepanes and benzothiazepines. 
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Our key interest is in the benzodiazepine class. We were interested to know if 
a thiazepine could also be active if a carbohydrate moiety replaces the benzene ring? 
To answer our question we developed a novel synthetic route to achieve our target 
thiazepene molecule which is discussed in Chapter 4. 
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Chapter 4 
Novel Reactions and Syntheses of Septanoses/Extended Ring Systems 
4. 1. Introduction 
The growing interest in septanose and septanoside sugars made us focus our 
efforts on doing synthesis in this area and to develop a convenient method for 
homologation of six membered ring sugars to serve as precursors for cyclic septanoses. 
Therefore the initial goal for our project was to develop a new methodology for the 
synthesis of septanoses using the ring opening of hexose sugars followed by the 
homologation of the acyclic sugar using a sulfur ylide, and subsequent recyclization of 
the chain-extended compound to the seven membered ring. We planned to start with a 
commercially-available hexose sugar, 2,3,4,6-tetra-O-benzyl-D-glucopyranose . Four 
divergent pathways were developed to generate four different target molecules. A 
summary of these pathways is shown in Figure 4.1. 
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4.2. Research Pathways 
Figure 4.1. Research Pathways. 
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4.3. Research strategy 
We have synthesized septanoses and large ring systems. This has been 
accomplished by: 
• Ring opening of a hexose sugar. 
• Stereoselective homologation of a carbon atom 
• Cyclization to the septanose sugar. 
Ring Opening: 
This methodology was designed to initiate the sequences with ring opening of the 
hexose sugar. Ring opening could be achieved in two ways: 
1- By the reduction of the starting hexose sugar 2,3,4,6-tetra-O-benzyl-D-glucopyranose 
to yield a diol (Scheme 4.1); or 
Bno~ Reduction BnO~OH 
BnOII • ~ OH 
---I...... BnOI"YOH 
-;-
BnO OBn BnO OBn 
1 39 
Scheme 4.1 
2- By subjecting the starting sugar to a Wittig olefination reaction to yield a homologated I 
I (unsaturated) intermediate. In this step ring opening and homologation can be carried 
out in one step process (Scheme 4.2 ). 
\ 
I 
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Bno}-O\AA Wittig RXN Bno*BnOI}.{~OH -----i~~ BnOI' ~~ 
BnO OBn BnO ~ OBn 
1 2 
Scheme 4.2 
Homologation: 
Our main goal for the project was to generate a convenient method for 
homologation of the carbon atoms in the chain by using sulfur ylide chemistry.76 Sulfur 
ylides are the epoxidation reagents that convert the carbonyl compounds into their 
epoxides in good yields. In the literature much work has been done to synthesize 
epoxides via sulfur ylides.76 The sulfur ylide mechanism involves nucleophilic attack of 
the ylide onto the carbonyl carbon. As a result, the carbonyl oxygen becomes an 
alkoxide anion. The displacement of the sulfide leaving group by the alkoxide produces 
an epoxide (Figure 4.2). 
Figure 4.2. Mechanism of sulfur ylide epoxidation. 
EpoxideSulfur ylide Carbonyl group 
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Another convenient epoxidation reagent we used was diiodomethyllithium. The 
mechanism of this epoxidation reaction is different from that of the sulfur ylides as 
shown in Figure 4.3. 
Figure 4.3. Mechanism of iodomethyllithium epoxidation. 
0 
LiMeLi uoy::' ..+ 12CH2 ..A k
R1 R2 R1 R2
R1 R2 
Ketone Epoxide 
Cyclization: 
Cyclization is the step in which we close the ring of the homologated sugar as a 
septanose. For this step, we planned two ways: 
1- By subjecting the Wittig product to a Hydroboration/Oxidation Reaction and then the 
intramolecular cyclization of the resulting hydroxyl sugar with the ketone can give a 
septanose with a hemiacetal. (Scheme 4.3), or 
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~ 
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Scheme 4.3 
2- By treating the dihalocompounds with reagents like thiourea to form a cyclized 
product. In this process homologation and cyclization is one-step process. 
Cyclization Bn0J-~ ...... NH 
.. Bno~~y 
BnO .: 
Bna: 
60X= CI 57 

X= Br, 58 

X= I, 59 

Scheme 4.4 
+ 
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Pathway-1 designed scheme: 
Bno~ Selective protection Bno~Reduction OH of primary -OH OH:::~OH ---I"~ BnOIl· OH .. BnO'" OTBOMS 
BnO OBn ~ ~ BnO OBn BnO OBn 
1 39 40 
BnO Homologation Bno* 
Oxidation o by epoxidation 0 
.. BnO~OTBDMS .. ,OTeoMSBnO"" 
BnO OBn BnO 'bBn 
41 42OH 

Deprotection/cyclization 
 ~f?o))
by TBAF 

BnO =. 

OBn 
43 
Scheme 4.5 
Pathway-1 was designed in a way that the pyranose sugar 1 will undergo 
reduction as a ring opening step and will yield a diol39. The primary alcohol of the diol 
39 would then be selectively protected as silyl ether 40 so that the secondary alcohol 
could be made a precursor for the epoxidation reaction. Therefore, 40 would be 
subjected to Swern oxidation to yield 41 which would then be homologated by 
epoxidation with a sulfur ylide to provide epoxide 42. Finally, the deprotection of the 
silylated hydroxyl of 42 by TBAF could generate an alkoxide nucleophile, which 
consequently will attack the less hindered carbon of the epoxide forcing intramolecular 
cyclization to yield 43 as a septanose (Scheme 4.5). 
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In this route, the ring opening step is favored by the reduction of 2,3,4,6-tetra-O­
benzyl-D-glucopyranose 1. Using literature methodology,77 2,3,4,6-tetra-O-benzyl-D­
glucitol 39 was synthesized successfully from 1 by treatment with NaBH4 in a mixture of 
EtOH and DCM in 86% yield (Scheme 4.6). Impurities were removed by flash 
chromatography (Si02). 
IRing openingj 
Bno* 
BnOI­ ~ OH 
e.:-BnO OBn 
.. 
EtOH/OCM, RT 16 h 
BnoyOH BnOII ' • OH 
'/BnO OBn 
1 
86% 39 
Scheme 4.6 
The glucitol 39, then underwent selective silylation of the more reactive primary 
alcohol, using TBDMSCI as the silylating reagent, in the presence of imidazole as a 
base and DMF as a solvent to produce 40 in 69% yield (Scheme 4.7}?8 The crude 
product was purified by column chromatography. 
Bn03={ TBOMSCI Bno)-o~OH 
BnOI ' ~ OH .. BnOI~XOTBOMS 
BnO OBn OMF, RT, 10 hr BnO OBn 
69% 
39 40 
Scheme 4.7 
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Compound 40 was then subjected to Swern oxidation according to the literature 
methodology 79 to synthesize a ketone 41 in 94 % yield {Scheme 4.8}. 
Bno~ (COClh BnoJo_OH 
..BnOI I ' .~ OTBDMS BnO')_{:OTBDMS 
DMSO, -78°C, 45 minBnO OBn BnO OBn 
94% 
40 41 
Scheme 4.8 
The epoxidation of the carbonyl group was next attempt using a slJlfur ylide as an 
epoxidation regent to give 42 (Scheme 4.9). 
IHomologation: I 
Bno _ BnoYo_Jo (CH3h-S+="CH2Bnol~H_OTBDMS BnOI )_.;. OTBDMS)( .. 

BnO OBn DMSO, RT, 24hr 
 BnO OBn 
41 42 
Scheme 4.9 
Unfortunately compound 42 was not obtained following this route. Instead, 
epoxidation of the carbonyl functionality also occurred with elimination of benzyl alcohol 
to yield EIZ 44 in 78%. The reason for the elimination reaction was the basicity of the 
sulfur ylide. 
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Homologation: 
Bno)=o_BnOI)_{~OTBDMS 
BnO OBn 
78% 
.. 
Bnoyo_H~ OTBDMS OR 
BnO OBn 
OBn 
&OTBDMS 
BnO OBn 
41 44 (Z - isomer) 44 (E - isomer) 
Scheme 4.10 
Here, the stereochemistry of alkene 44 is worth mentioning. Since the allyl 
epoxide may still be prone to cyclization in its Z-isomer form, we proceeded to the 
deprotection of the alcohol and subsequent cyclization to afford the septanose. Here, 
the stereochemistry of the alkene 44 did not allow the cyclization to occur presumably 
because the alkene existed in the E-conformer. Deprotection of compound 44 using 
TBAF gave an epoxy alcohol 45 in 85 % yield (Scheme 4.11). 
Bno~o OTBDMS 
44 (Z - isomer) ~ ~ 0Bn 
BnO OBn TBAF 
, OH
..OR o "fX-
OBn THF, 0 °c, 4 h BnO 
~ 
'OBn 
44 (E - isomer) OTBDMS 87% 
o . 45~
BnO 
~ 
OBn 
Scheme 4.11 
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NOESY NMR was used to confirm the formation of E-confomler of 44. The 
results were not conclusive to confirm the formation of E-conformer as the alkene 
proton does not have any neighboring proton in the structure. 
We did not get the desired cyclized septanose; therefore, we changed the 
epoxidation method. In this case, we used diiodomethyllithium as an epoxidation 
reagent to avoid the elimination reaction. 8o An epoxide 42 was achieved in 76% yield 
without the loss of a benzyl alcohol group (Scheme 4.12). 
IHomologation: 
Bno)=o. BnoYo_Bnol,~xoTBDMS Bno'~H__OTBDMS
..BnO OBn 
BnO OBnTHF, ooC 
76%41 42 
Scheme 4.12 
Cyclization was carried out by the deprotection of the alcohol by using TBAF to 
afford 43 as a septa nose (Scheme 4.14). The problem encountered during the 
deprotection step was the presence of moisture in the commercially-available TBAF. 
We came to know this by examination of the literature which says that the commercially­
available TBAF contains almost 5% H20.81 When the deprotection was carried out with 
commercially available TBAF, product 42 did not cyclize; instead it gave an epoxy-
alcohol 46 due to quenching of the alkoxide with water (Scheme 4.13). Since, we 
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instead wanted an intramolecular cyclization to occur keeping the reaction environment 
anhydrous became a high priority. 
ICyclization: 
TBAF 
BnoYo_ Commercially Available BnoYo_ 
BnOI X OTBDMS .. BnOIX.OH 
BnO OBn BnO OBn 
46 
42 
Scheme 4.13 
Therefore, we dried commercially-available TBAF over molecular sieves (3A) 
overnight and conducted the reaction in a totally anhydrous environment to prepare the 
cyclic seven membered ring sugar 43. 
ICyclization:1 
OH 
TBAFBnoYo _ 
Dried on Mol. Sieves (3A) BnOI ~ OTBDMS 'WR~ 
.. BnO .=.BnO OBn OBn72% 
42 43 
Scheme 4.14 
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Scheme 4.15 
In Pathway 2, ring opening and the homologation was carried out in a one-
step reaction by subjecting the starting sugar 1 to a Wittig reaction, using literature 
methodology,82 yielding an acyclic extended chain sugar 2 in 75% yield (Scheme 4.16)_ 
Bno)­
BnOI'~OH 
-----..... 
Bno)
--OH 
BnO:' -! 
BnO OBn THF,RT 
75% BnO 
~ 
OBn 
1 2 
Scheme 4.16 
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The oxidation of the hydroxyl group of 2 was done by a Swern oxidation which 
yielded compound 47 in 80% yield (Scheme 4.17). 
OHBno*

BnOI' __ _ 
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BI10 OBn 
2 
(COCI)2. 0MSO 
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OCM, -78°C 
80% 
Scheme 4.17 
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BnO OBn 
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The alkene moiety of compound 47 was subjected to a hydroboration/oxidation 
reaction by using BH3THF (Scheme 4.18). The drawback of using this reagent was, 
instead of hydroborating the alkene moiety, it reduced the the ketone to the alcohol 2 
(Scheme 4.18). 
OH 
Bno)= 
BH3·THF Bno~o"B"O)_~~ X ..... Bno~H 
BnO OBn NaOH, H20 2 BnO :: OBn 
4947 
Scheme 4.18 
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Scheme 4.19 
Dicyclohexyl borane was next attempted because it is a specific reagent for the 
selective hydroboration/oxidation of the alkene moiety without reducing the carbonyl 
group if present in the molecule.83 Not all bulky borane reagents have that property. 
Dicyclohexyl borane is not commercially available due to its poor stability. Therefore, it 
is synthesized either in-situ or separately. We tried both ways of synthesizing the 
borane reagent and then subjected the alkene to hydroboration/oxidation. The results of 
two trials are summarized in Table 4.1. 
Table 4.1. Trials of Dicyclohexylborane reductions. 
• Trial Borane reagent Synthesized in-situ Synthesized separately Reaction 
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Scheme 4.20 
After several trials of hydroboration/oxidation reactions with different conditions in 
which 47 was unaffected, we decided to do molecular modeling of the compound to look 
at the conformation of the molecule. Using Chern 3-D software we used MM2 
calculations to minimize the energy of the structure (Figure 4.3). From the minimized 
structure obtained we came to know that alkene and carbonyl moieties are close to 
each other and perhaps bulky reagents like dicyclohexyl borane are not able to react 
because of steric hindrance between the two groups. While, with the use of non-bulky 
reagents, the carbonyl functionality was first reduced. Another option would have been 
to protect the carbonyl first and then perform the hydroboration/oxidation reactions. 
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Figure 4.3. Molecular modeling of compound 47. 
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In the model of 47 (Figure 4.3), carbon and oxygen atoms of the carbonyl group 
are labeled as C(1) and 0(6) respectively. While, the carbon and hydrogen atoms of 
alkene (-CH=CH2) are labeled as C(5), C(31), H{41), H(42) and (H43). To see the 
specific atom causing hindrance in two functional groups, measurements were 
calculated to generate all atoms with close contacts. The results are listed in Table 4.2. 
Table 4.2. Molecular modeling simulation results. 
Atoms in close 
contacts 
Actual distance between 
atoms (o/A) 
Calculated (u/A) 
1 C(1) - H{43) 1.8521 1.9 
2 C(1) - C(5) 2.5218 2.5 
3 0(6) ­ H(43) 1.3762 1.4 
14 0(6) ­ C(5) 1.8934 1.9 
5 
1 
0(6) ­ C(31) 2.6620 2.7 
On the basis of the calculated values, it is concluded that distance between the 
hydrogen atom of alkene H(43) and the oxygen atom of ketone O(6) is the least (1.4 °/A) 
among all which is the reason of steric hindrance. 
Failure to achieve the desired compound led us to two more divergent pathways; 
pathway 2A and pathway 28. 
I 
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Scheme 4.21 
In this pathway, compound 2 was synthesized as reported in pathway 2. To 
compound 2 was carried out hydroboration oxidation reaction to achieve a diol 50 
(Scheme 4.21) so that primary alcohol of the resulting diol would have been subjected 
to selective oxidation consequently cyclize intramolecularly to yield 51. 
The hydroboration oxidation reaction was monitored by thin layer 
chromatography which showed that starting material 2 remained unchanged and was 
recovered as it is. 
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OBn BnO OBn 
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Scheme 4.22 
Here, the protection of alcohol group was necessary as literature shows that the 
reaction of borane reagents with various oxygen containing functional groups (e.g. -OH) 
is competitive with hydroboration reactions. 84 
The alternative route was the protection of the alcohol group, but we did not 
encourage that idea as the protecting group would give steric hindrance to the alkene 
functionality of the compound, like in compound 47. To strengthen our idea, we tried to 
protect the alcohol moiety of compound 2 with silyl ether. The yield of the silylated 
product 52 was extremely low (8%)(Scheme 4.23). Compound 52 was the subjected to 
hydroboration oxidation reaction on small scale. The reaction was monitored by thin 
layer chromatography which showed that reaction did not work and the starting material 
remained intact. 
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Bno~ BnO, BnO,OH NaH/THF (OTBDMS BH THF ;-OTBOMSBnOI' -= BnOI' _ 3' Bnol>~OH 
BnO bBn TBDMSCI••::. 24 h Bnoi-Cn .Na~;' BnO OBn 
8.0% 52 532 
Scheme 4.23 
The divergent pathway 28 was then followed. 
Pathway 28: 
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OBn 
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Scheme 4.24 
In this pathway, the alkene functionality of 2 was expected to convert to epoxide 
54 (Scheme 4.24). The deprotonation of alcohol of 54 using sodium hydride as a base 
was rationalized to yield a cyclic septanose 55 by the attack of alkoxide to the less 
hindered carbon of the epoxide. 
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Bno<}zOH mCPBA, NaHC03 OHBno'kBnO:' ,_ )( --Il1o- BnOI' , 0 
'-;;,. 
-:;.,OBn CH2CI2, RT, 12 h BnO BnO OBn 
542 
Scheme 4.25 
Compound 2 was subjected to an epoxidation reaction using mCPBA reagent but 
reaction did not work and compound 2 was recovered and confirmed by NMR. 
Pathway-3 designed scheme: 
IRing openingl Homologation I ICyclization I 
Bno Bn°l- ,oBn01-OH NaHJ sno,:uBnOl' ~9sno")--tOH ~ '-7t -----.. 
BnO OBn BnO ~ OBn BnO ;. OH 
OBn 
55541 
Scheme 4.26 
This pathway was designed with the alternative epoxidation reagent 
iodomethyllithium which successfully worked with silylated carbonyl compound 41 in 
pathway-1. To minimize the number of steps of the reaction we planned to make the 
epoxide from the carbonyl moiety of the starting sugar 1. In this pathway, ring-opening 
and homologation would be a one step process. Later, 54 could be treated with a base 
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such as NaH which could abstract the proton of the secondary hydroxyl group and 
generate a nucleophile for attack onto the less hindered carbon of the epoxide, resulting 
in cyclization to 55. 
Unfortunately, when we treated the starting sugar with the epoxidation reagent, 
instead of epoxidation of the aldehyde group, the anomeric hydroxyl group was 
methylated (Scheme 4.28). Here, iodomethylithium worked by inserting between the 
oxygen and hydrogen atoms of the anomeric hydroxyl group. 
Bno)-O\ABnO~~OH :nn~~ 
BnO /OBn )( ... BnO OBn 
1 THF, OoC 54 
Scheme 4.27 
The resulting compound 56 is a commercially available compound and data 
analysis (MS, NMR 1H and 13C DEPT) confirmed the formation of p-isomer of 56. We 
did not achieve our target molecule 54 but came up with a new method of preparing the 
methyl glycoside 56. 
Bno,­ Bno)-o\~
BnOI < °YOH 
... BnOI~X~OCH3
;--<~ 
BnO "OBn BnO OBnTHF, OoC 
561 83% 
Scheme 4.28 
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Scheme 4.29 
This pathway was designed to synthesize a target molecule with a thiazepine 
template. As previously mentioned we wanted to see the effects replacing the benzene 
moiety of a benzothiazepine with a sugar moiety. For this purpose, we designed a 
pathway in which ring opening was carried out by reduction of 1 as we did before. The 
diol 39 would then be converted to the dihalo compound. Initially we wanted to 
brominate the diol because later the bromo groups could serve as good leaving groups 
in the cyclization reaction with thiourea. 
Using a literature procedure, 85 thionylbromide was used as a bromination 
reagent and was reacted with diol 39 (Scheme 4.30). Unfortunately, the reaction was 
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not successful and product 57 was not obtained. Alternate conditions (Table 4.3) were 
tried but product 57 did not form. Benzyl alcohol was consistently isolated as a reaction 
by-product suggesting elimination was occurring from our material. 
SOBr2 Bno~Br 
BnOIl. ~ Br)( ... 
OeM, RT, 2 h ~ BnO OBn 
39 57 
Scheme 4.30 
After the failure of Scheme 4.30 we switched the halogenation reagent to thionyl 
chloride. After different trials we were able to achieve 58. However, no reaction 
occurred with 58 was treated with thiourea. We concluded that the chloro groups were 
stable to the thiourea displacement conditions, most likely due to the weak 
nucleophilicity of thiourea. 
Bno~OH BON NHBno~CI ~nOIII'. tBnOIi' 'i OH BnOI I • 'i CI.. 
~ ~ ~ ~ BoO ~ BnO OBn oeM, 2 h BoO OBn 
BnC 
39 58 60 
Scheme 4.31 
The last attempt we made for the dihalo intermediate was to use an iodination 
reaction. Using a literature procedure, 86 we tried to synthesize diiodo intermediate 59. 
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Again, instead of the desired diiodo compound, benzyl alcohol was the major byproduct 
isolated, 
I 
I 
I 
I 
I 
BnO}{H Nal, TMSCI Bno~ 
BnOII. '. OH BnO'" I, 1 
_ X .. 
~ Acetonitrile BnO ~ OBnBnO OBn 
5939 
Scheme 4.32 
Table 4,3. Summary of halogenation reactions. 
Reagent I RXN 
Temp.
DC 
RXN 
Time 
h 
Quenching I Product 
Temp. 
i 57,58,59DC 
Product 
60 
By-product I 
SOBrz RT 2 RT NO - BnOH 
0 2 RT NO - BnOH 
PBr3 RT 
I 
5 0 NO - BnOH 
i SOClz RT 1 RT NO -
RT 2 RT NO -
50 1 RT 0 -
RT 4 0 53 NoRXN 
Nal 
I 
RT 5 RT NO 
I 
- BnOH 
ND = Not Detected 
D = Decomposed 
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I After the failure of the halogenation reactions, an alternative intermediate was 
J j planned for the reaction with thiourea. From the failure of the halogenation reaction it 
I 
~ 
l was concluded that halo-groups which are supposed to be good leaving groups were 
1 
not amenable to the cyclization conditions with thiourea. Therefore, we thought of 
making a dicarbonyl intermediate that could serve as a source of a good electrophile for 
the thiourea. In the literature we found evidence for the reactions of urea with carbonyl 
groups to give imines.87 
Keeping all these points in mind, we planned a one pot synthesis of a di­
carbonyl compound 61 as an intermediate starting from diol 39 (Scheme 4.33). 
According to the literature this compound is unstable and prone to hydrolysis. The di­
carbonyl compound 61 was made as an intermediate in-situ by Swern oxidation of 
compound 39. After the completion of the reaction, thiourea was added directly to the 
di-carbonyl compound 61. To our astonishment, we observed a spot on TLC plate which 
turned yellow in PdCh dip (an indication of the presence of sulfur in the molecule). 88 
When we worked-up the reaction we are able to isolate the product as a white solid. It 
was noticed that when thiourea was added in the reaction mixture at room temperature, 
the % yield of the overall reaction was low (27%) while when thiourea was added at -78 
DC, the yield was increased up to 58%. Later, MS, NMR (H1 and C13), IR confirmed that 
the new compound was indeed our desired target molecule 62. 
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Bn01={OH 
BnOI­ ~ OH 
BnO OBn 
Swern 
Oxidation 
... [::1=<:01 
s 
JlH2N NH2 
.. 
BnO OBn 43% 
OH 
~ BnO N S BnO". y NH BnO • .::: 
BnO OH 
39 61 62 
Scheme 4.33 
As we have mentioned before, there is no evidence in the literature for this kind 
of reaction, but our further study of the literature led us to a similar kind of reaction, 
called the Bignelli reaction. The Bignelli reaction is an acid catalyzed 3-component 
cyclization reaction, in which a urea,a ~-ketoester and an aldehyde cyclize together to 
yield dihydropyrimidone. 89 
Figure 4.4. Bignelli reaction. 
Ph 
EtOH 
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4.5. Summary 
For this project we designed multi-step synthetic pathways to synthesize a stable 
septanose and a heterocycle based upon a benzothiazepine structure. We developed 4 
divergent routes for these pathways out of which we were able to achieve pathway-1 
and pathway-4 successfully. Pathway-1 was made successful by altering the 
epoxidation reagent while pathway-4 was made successful by changing the dihalo 
intermediates with dicarbonyl compounds. Halogenation reactions failed with the use of 
brominating reagents like phosphorus tribromide and thionylbromide and the byproduct 
of those reactions was benzyl alcohol. Halogenation reactions worked with thionyl 
chloride to yield the dichloro intermediate but the final cyclized product could not be 
formed presumably because chloro-groups are not as good leaving groups as bromo­
groups. 
In consequence, because the halogenation reactions did not work, carbonyl 
electrophiles were tried in the reactions with thiourea and yielded a cyclized eight­
membered ring product. 
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Chapter 5 

Summary 

5. 1. Conclusions 
Carbohydrates are versatile synthetic precursors. Our main goal of this project 
was to synthesize a stable septanose sugar starting from a hexose sugar. There are 
syntheses reported in the literature for septanoses but no known homologation methods 
using classic epoxidation reagents, the sulfur ylides. 
Halogenation reactions failed with the use of brominating reagents like 
phosphorus tribromide and thionylbromide and the by-product of those reactions was 
benzyl alcohol. Halogenation reactions worked with thionyl chloride to yield the dichloro 
intermediate but the final cyclized product could not be formed in the reaction with 
thiourea. It could also be concluded that thiourea is not a very good nucleophile for this 
reaction. 
The new methodology we have developed includes a new way to epoxidize the 
sugars as well as to cyclize the dicarbonyl intermediate with urea or thiourea. The 
heterocycles obtained could serve as new therapeutics. Because of the versatility in the 
structure of sugar molecules a number of derivatives can be synthesized using this new 
methodology. 
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5.2. Experimental 
5.2.1. General methods: 
All reactions were carried out under nitrogen in oven-dried glassware unless otherwise 
mentioned. For moisture sensitive reactions, anhydrous solvents were used and 
reagents were added to the reaction mixtures through syringes. All reactions were 
monitored by thin layer chromatography (TLC). Column chromatography was carried 
out by using Silitech 32-63 D (230-400 mesh) silica gel. 1H and 13C NMR spectra were 
recorded on a 500 MHz Varian Inova spectrometer in chloroform-d or acetone-de as 
solvent using tetramethylsilane as an internal standard. Infrared spectra were recorded 
on a Nicolet FT-IR. Mass spectral analyses were performed at the University of IIlinois­
Champaign-Urbana using electrospray ionization (ESI). 
S.2.2. (2R,3R,4R,SS)-1 ,3,4,S-tetrakis(benzyloxy)hept-6-en-2-ol (2) 
To a suspension of Ph3MePBr (7.93 g, 22.20 mmol) in THF (50 mL) at -20 DC, was 
added dropwise 1.6 M BuLi in hexane (15 mL). The mixture was stirred at -20 DC for 15 
min, at RT for 1 h, and then cooled again to -20 DC. To this was added dropwise a 
solution of 1 (3.0 g, 5.55 mmol) in THF (15 mL). The mixture was stirred at -20 DC for 15 
min and RT for 6 h, acetone (30 mL) was added and the mixture was stirred at RT for 
30 min. EhO (100 mL) was added and the precipitate of Ph3PO was removed by 
filtration through Celite. The filter was rinsed with EhO and the combined filtrate and the 
washings were washed with aq sat. NaHC03 (50 mL), then brine (50 mL), dried over 
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Na2S04. filtered and concentrated at reduced pressure. The residue was purified by 
flash chromatography (Hexanes-EtOAc, 4:1) to afford 2 (2.20 g, 76%) as a colorless oil. 
1H and 13C NMR data for this compound were consistent with literature values.9o 
S.2.3. 2,3,4,6-tetrakis(benzyloxy)hexane-1,S-diol (39): 

Commercially-available 2,3,4,6-tetra-O-benzyl-O-glucopyranose (9.0 g, 16.65 mmol) 1 

was taken in an oven-dried, 1000 mL round bottom flask. EtOH/OCM (1:1) (140 mL) 

was added and the solution was stirred for 15 min at room temperature. NaBH4 (3.0 g, 

79.3 mmol) was added as a single portion and the reaction was stirred for 16 h at room 

temperature. After the completion of the reaction, 2M HCI (30 mL) was added to the 

reaction mixture and it was stirred for an additional 5 min. The organic layer was 

extracted in dichloromethane (2 x 20 mL). The organic layers were combined and dried 

over Na2S04. The solvent was evaporated under reduced pressure to afford crude 

compound that was purified by flash chromatography (Hexanes/EtOAc, 3: 1) to yield 39 

(8.4 g, 93.4%) as a colorless oil. 

1H and 13C NMR data for this compound were consistent with literature values.77 

S.2.4. 1 ,3,4,S-tetrakis(benzyloxy)-6-«tert-butyldimethylsilyl)oxy)hexan-2-ol (40): 

To a well-stirred solution of 39 (3.0 g, 5.52 mmol) in OMF (anhydrous, 20 mL) was 

added imidazole (0.4 g, 7.17 mmol) and the temperature was brought to OOC. The 

reaction was stirred for 20 min at OOC and TBOMSCI (0.91 g, 6.0 mmol) was added. The 

reaction mixture was brought to RT and stirred for an additional 24 h. After the 

completion of the reaction, water (20 mL) was added and the aqueous layer was 
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extracted with CH2CI2 (3 x 20 mL). The combined organic layers were dried over 
Na2S04, decanted and concentrated under reduced pressure. The residue was purified 
by flash chromatography (Hexanes/EtOAc, 3:1) to afford 40 (2.0 g, 66.6%) as a 
colorless oil. 
1H and 13C NMR data was consistent with literature values. 91 
5.2.5. 1 ,3,4,5-tetrakis(benzyloxy)-6-«tert-butyldimethylsilyl)oxy)hexan-2-one (41): 
To the solution of oxalyl chloride (0.6 mL, 6.80 mmol) in CH2CIz (20 mL) was added a 
solution of DMSO (1.0 mL, 13.70 mmol) in CH2CIz (5 mL) via dropping funnel at -78°C. 
The reaction mixture was stirred for 5 min and then a solution of 40 (4.0 g, 62.0 mmol) 
in CH2CI2(5 mL) was added. It was stirred for an additional 15 minutes and TEA 
(triethylamine) (4.3 mL) was added. Water (25 mL) was added and the aqueous layer 
was extracted with CH2CI2 (3 X 20 mL). The combined organic layers were dried over 
Na2S04 and the solvent was removed under reduced pressure. The residue was 
purified by flash chromatography (Hexanes/EtOAc, 4:1) to afford 41 (3.1 g, 79%) as a 
colorless viscous compound. 
1H and 13C NMR data was consistent with literature values.92 
5.2.6. tert-butyldimethyl«2S,3R,4S)-2,3,4-tris(benzyloxy)-4-(2­
«benzyloxy)methyl)oxiran-2-yl)butoxy)silane (42): 
To the solution of 41 (2.5 mmol) and diiodomethane (0.3 mL, 3.75 mmol) in THF (10 
mL) was added dropwise methyllithium (3.4 mL of 1.5 M solution in diethyl ether, 5 
mmol) over 5 min and under nitrogen at 0 °c for 30 min. The mixture was stirred for one 
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additional hour at room temperature. The resulting mixture was poured on ice and 
extracted with OCM (3 x 10 mL). The combined organic layers were dried over Na2S04, 
filtered and the solvent was removed under reduced pressure to yield 42 as colorless oil 
in 56% yield. Compound 42 was used for the next step without purification. 
5.2.7. (2S,Z)-2,3-bis(benzyloxy )-4-(2-( (benzyloxy)methyl)oxiran-2-yl)but-3-en-1-ol 
(43). 
A solution of 42 (30.0 mg, 0.053 mmol) and THF (2 mL) was cooled to 0 DC and TBAF 
(18 mg) (commercially available TBAF was made anhydrous by adding 3A molecular 
sieves) was added. The mixture was allowed to stir for 45 minutes. After the completion 
of the reaction, cold water (25 mL) was added and it was extracted in CH2Cb (3 x 5 mL). 
The combined organic layers were dried over Na2S04 and the solvent was removed 
under reduced pressure. The residue was purified by flash chromatography 
(Hexanes/EtOAc, 3:1) to afford 43 (0.021 mg, 72%) as a colorless oil. 
1H NMR (500 MHz, COCb): 8 7.36 - 7.26 (m, 20 H), 4.69 - 4.60 (m, 2 H), 4.59 - 4.50 
(m, 8 H, CH2Ph), 3.91 - 3.85 (m, 2H), 3.82 - 3.72 (m, 3 H), 3.65 - 3.60 (m, 2H). 
13C NMR (500 MHz, COCb): 8= 139.0,138.0,137.3,136.0,128.6-128.7 (20 C), 85.1, 
82.2, 81.8, 81.1, 77.5, 74.5,74.0, 73.3, 73.2, 72.4, 72.3, 72.2, 72.1, 71.5, 70.5, 69.2, 
61.1, 61.6, 59.1,58.0, 48.8, 46.6. HRMS calcd for C35H3S0S [M+Nar: 577.2566, found 
577.2568. 
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5.2.8. tert-butyldimethyl«2S,3R,4S)-2,3,4-tris(benzyloxy)-4-(2­
«benzyloxy)methyl)oxiran-2-yl)butoxy)silane (44) 
NaH (60% dispersion in mineral oil) (87 mg, 3.66 mmol) was taken in a reaction flask 
and washed with hexanes. To the flask, DMSO (5 mL) was added and the reaction was 
stirred for 25 min. Trimethylsulfonium iodide (0.6 g, 2.88 mmol) was then added to the 
reaction flask and the mixture was refluxed for 30 min. then cooled to room 
temperature. A solution of 41 (1.6 g, 2.44 mmol) dissolved in DMSO (5 mL) was added 
to the reaction mixture and it was stirred for 1 h. After the completion of the reaction, 
cold water (25 mL) was added and it was extracted in CH2Cb (3 x 10 mL). The 
combined organic layers were dried over Na2S04 and the solvent was removed under 
reduced pressure. The residue was purified by flash chromatography (Hexanes/EtOAc, 
3: 1) to afford 44 (1.05 g, 64%) as a colorless oil. 

1H NMR (500 MHz, CDCb): 8 = 7.38-7.26 (m, 15 H), 5.15 (dd, J = 5.5, 4.0 Hz, 1 H), 4.85­
4.35 (m, 6H, 3 CH2Ph), 3.84 (d, J = 10 Hz, 1H), 3.78-3.65 (m, 2H), 3.58-3.51 (m, 2H), 

2.98-2.84 (m, 2H), 0.9 (s, 9H, CH3Si-), 0.01 (s, 6H, CH2Si-). 

13C NMR (500 MHz, CDCb): 8= 139.0,138.0,137.3,128.6-128.7 (15 C), 113.6,74.3, 

73.9,73.6,70.7,70.3,66.3,57.8,51.0,26.1, 18.60. HRMS calcd for C34H4405Si 

[M+Nat 583.6, found 583.2. 

5.2.9. (4S,5R,6S)-4,5,6-tris(benzyloxy)-3-«benzyloxy)methyl)oxepan-3-ol (45) 
A solution of 44 (20.0 mg, 0.03 mmol) in THF (4 mL) was stirred 0 °c for 15 minutes. 
TBAF in THF (0.04 mmol, 0.04 mL) was added and the mixture was warmed to room 
temperature and stirred an additional 45 minutes. After the completion of the reaction, 
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cold water (25 mL) was added and it was extracted with CH2Cb (3 x 5 mL). The 
combined organic layers were dried over Na2S04 and the solvent was removed under 

reduced pressure. The residue was purified by flash chromatography (Hexanes/EtOAc, 

4:1) to afford 45 (11.3 mg, 68%) as a colorless oil. 

1H NMR (500 MHz, CDCb): 8 =7.38-7.26 (m, 15 H), 5.15 (dd, J =5.5, 4.0 Hz, 1H), 4.85­
4.35 (m, 6H, 3 CH2Ph), 3.84 (d, J = 10 Hz, 1H), 3.78-3.65 (m, 2H), 3.68-3.61 (m, 2H), 
3.46 (s, 1H, OH), 2.98-2.84 (m, 2H). 

13C NMR (500 MHz, CDCb): 8 = 139.0,138.0, 137.3, 128.6-128.7 (15 C), 113.6,74.3, 

73.9,73.6,71.2,70.7,70.3,66.3,57.8,51.0. HRMS calcd for C2sH300sSi [M+Nat 

469.2093, found 469.1993. 

5.2.1 o. (2S,3R,4S)-2,3,4-tris(benzyloxy)-4-(2-«benzyloxy)methyl)oxiran-2-yl)butan­
1-01 (46) 

A solution of 42 (50.0 mg, 0.074 mmol) in THF (10 mL) was stirred at 0 °c for 15 min. 

TBAF (0.07 mmol, 0.07 mL) was added and the reaction was warmed to room 

temperature and was stirred for an additional 1 h. After completion of the reaction, cold 

water (50 mL) was added and it was extracted in CH2CI2 (3 x 10 mL). The combined 

organic layers were dried over Na2S04 and the solvent was removed under reduced 

pressure. The residue was purified by flash chromatography (Hexanes/EtOAc, 4: 1) to 

afford 46 (29 mg, 73%) as a colorless oil. 

1H NMR (500 MHz, acetone) 8 =7.36 - 7.27 (m, 20 H), 4.75 - 4.07 (m, 10 H) 4.83 - 4.76 

(m, 2H), 3.99 (m, 1 H), 3.74 (m 1 H), 3.65 (m, 1 H), 2.93 (d, J=5.61 HZ,1 H), 2.82 (s, 1 H), 

2.79 (d, J=5.61 Hz, 1 H). 
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HRMS calcd for C35H3S06 [M+Ht: 555.2741, found 555.2741. 
5.2.11 (3S,4R,5S)-1 ,3,4,5-tetrakis(benzyloxy)hept-6-en-2-one (47) 
To a suspension of Dess-Martin periodinane (183 mg, 0.43 mmol) in CH2Ch (5 mL) was 
added a solution of 2 (80 mg, 0.14 mmol) in CH2Ch (2 mL) at RT and the mixture was 
stirred for 30 min. Et20 (20 mL) and 10% aq Na2S203 solution (10 mL) were added and 
the mixture was stirred for 10 min. The phases were separated and the aqueous phase 
was extracted with Et20 (2 x 10 mL). The combined organic phases were washed with 
sat.aq NaHC03 (15 mL), brine (15 mL), dried over Na2S04, filtered and concentrated 
under reduced pressure. The residue was purified by flash chromatography (Hexane-
EtOAc, 4:1) to afford 47 (70 mg, 91%) as a colorless oil. 
1H NMR (500 MHz, CDCb): 8 =7.33 -7.23 (m, 20 H), 5.79 (ddd, J=17.24, 10.40,7.87 
Hz, 1 H), 5.34 - 5.29 (m, 2 H), 4.44 - 4.34 (m, 8 H), 4.22 (d, J=8.85 Hz, 1 H), 4.82 - 4.76 
(m,2 H), 3.92 (dd, J=6.77, 3.48 Hz, 1 H), 3.62 (m, 1 H). 
13C NMR (500 MHz, CDCI3): 8=206.7,138.5,138.4,138.3,138.1,129.3 -127.5 (20 
C), 118.9, 81.5, 81.3, 78.5, 74.7, 73.3, 73.2, 71.3, 70.7, 70.4. MS calcd for C35H3605 
[M+Nat: 559.0, found 559.2. 
5.2.12. (2R,3R,4S,5R)-3,4,5-tris(benzyloxy)-2-«benzyloxy)methy1)-6­
methoxytetrahydro-2H-pyran (56) 
To the solution of 1 (2.5 mmol) and diiodomethane (0.3 mL, 3.75 mmol) in dry THF (10 
mL) at 0 °c was added dropwise methyllithium (3.4 mL of 1.5 M solution in diethyl 
ether, 5 mmol) over 5 min. The mixture was warmed to room temperature and was 
stirred for one additional hour. The resulting mixture was poured on ice and extracted 
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with OCM (3 x 10 mL). The combined organic layers were dried over Na2S04, filtered, 
and the solvent was removed under reduced pressure to yield 56 in 56% yield. 
1H and 13C NMR data was consistent with literature values. 101 
5.2.13. (5S,6R, 7R)-5,6, 7 -tris(benzyloxy)-4-«benzyloxy)methyl)-4,8-dihydroxy-1 ,3­
diazocane-2-thione (62) 
To a solution of oxalyl chloride (0.6 mL, 6.80 mmol) in CH2Cb (10 mL) was added a 
solution of OMSO (1.0 mL, 13.70 mmol) in CH2Cb (5 mL) via dropping funnel at -78°C. 
The reaction mixture was stirred for 5 min and then a solution of 39 (0.6 g, 1.10 mmol) 
in CH2Cb (5 mL) was added. It was stirred for an additional 15 min and TEA 
(triethylamine) (2.3 mL) was added and it was stirred for another 20 minutes. Then the 
mixture was warmed to -60°C and thiourea (0.15 g, 1.84 mmol) was added. The 
reaction mixture was slowly warmed to RT and was stirred for 24 h. Water (15 mL) was 
added and the aqueous layer was extracted with CH2CI2 (3 X 10 mL). The combined 
organic layers were dried over Na2S04 and the solvent was removed under reduced 
pressure. The residue was purified by flash chromatography (Hexanes/EtOAc, 4:1) to 
afford 62 as white solid (0.26 g, 43%). 
1H NMR (500 MHz, COCh): 8 = 7.36 - 7.26 (m, 20 H), 4.90 (d, 2 H), 4.80- 4.47, 8 H), 
3.57 (d, J=9.33 Hz, 2 H), 3.48 (s, 2 H), 3.41 (d, J=9.94 Hz, 2 H), 3.37 - 3.28 (m, 2 H). 
13C NMR (500 MHz, COCI3): 8 = 184.6,138.2,137.9,137.3,137.0,128.8-127.8 (20 C), 
97.45,81.9,79.8,79.7,78.3,75,8,75.6,75.4,73.7, 71.3. HRMS calcd for C35H3SN20SS 
[M+Ht: 615.2529, found 615.2524. 
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